Atwood & Palmer Inc. grew its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 1.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 194,376 shares of the company’s stock after acquiring an additional 3,524 shares during the period. AbbVie comprises about 2.5% of Atwood & Palmer Inc.’s portfolio, making the stock its 10th largest holding. Atwood & Palmer Inc.’s holdings in AbbVie were worth $44,413,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of ABBV. Chelsea Counsel Co. bought a new position in shares of AbbVie in the 3rd quarter valued at about $26,000. Westend Capital Management LLC bought a new position in shares of AbbVie in the 4th quarter valued at about $29,000. Texas Capital Bancshares Inc TX bought a new position in shares of AbbVie in the 3rd quarter valued at about $31,000. WestEnd Advisors LLC grew its position in shares of AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares during the period. Finally, Caitlin John LLC bought a new position in shares of AbbVie in the 3rd quarter valued at about $33,000. Institutional investors own 70.23% of the company’s stock.
AbbVie Stock Performance
Shares of ABBV stock opened at $200.97 on Friday. The company has a market capitalization of $355.34 billion, a price-to-earnings ratio of 85.15, a PEG ratio of 0.72 and a beta of 0.38. The company has a 50-day simple moving average of $217.33 and a 200 day simple moving average of $222.62. AbbVie Inc. has a 52 week low of $176.11 and a 52 week high of $244.81.
AbbVie Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.4%. AbbVie’s payout ratio is currently 293.22%.
Wall Street Analyst Weigh In
ABBV has been the subject of a number of analyst reports. UBS Group decreased their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research report on Thursday, February 5th. Piper Sandler decreased their price objective on shares of AbbVie from $299.00 to $294.00 and set an “overweight” rating for the company in a research report on Thursday. Evercore reduced their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a report on Wednesday, February 4th. Citigroup reduced their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a report on Tuesday, January 27th. Finally, Cantor Fitzgerald reduced their target price on shares of AbbVie from $250.00 to $240.00 and set an “overweight” rating for the company in a report on Wednesday, April 8th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $253.19.
Read Our Latest Research Report on ABBV
Insider Transactions at AbbVie
In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. This represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.06% of the company’s stock.
AbbVie News Roundup
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: AbbVie announced a $1.4 billion, 185‑acre advanced manufacturing campus in Durham, NC to produce immunology, neuroscience and oncology medicines; the investment is AbbVie’s largest single-site capital commitment and should support capacity, vertical integration and long‑term growth. AbbVie to build $1.4 billion manufacturing campus in North Carolina
- Positive Sentiment: Canaccord initiated coverage with a strong‑buy/Buy stance and a $262 price target, adding an analyst catalyst and incremental buy-side attention that may support near-term buying interest. AbbVie (ABBV): The Best Stock to Buy on a Pullback
- Positive Sentiment: AbbVie inked an exclusive licensing agreement with Haisco Pharmaceutical Group for pain‑medicine development, extending its pipeline and potential future product/IP upside. AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development
- Neutral Sentiment: AbbVie is set to report Q1 2026 earnings on April 29; consensus estimates (Zacks) call for revenue around $14.78B and EPS near $2.69 — the print and management commentary could be a short‑term volatility trigger. AbbVie Q1 Earnings Loom: Buy or Sell the Stock Ahead of Results?
- Neutral Sentiment: Media and investor pieces highlighting AbbVie as a “buy on a pullback” or attractive dividend/biotech play add background interest but are not immediate catalysts without fresh fundamentals or trial readouts. AbbVie (ABBV): The Best Stock to Buy on a Pullback (InsiderMonkey)
- Negative Sentiment: The U.S. FDA has declined to approve AbbVie’s trenibotulinumtoxinE (TrenibotE) wrinkle treatment, citing manufacturing issues — that regulatory setback delays potential cosmetic-market revenue and introduces execution risk around manufacturing remediation. US FDA declines to approve AbbVie’s wrinkle treatment (Reuters)
- Negative Sentiment: AbbVie confirmed receipt of a Complete Response Letter (CRL) from the FDA for the TrenibotE BLA related to manufacturing processes; while the agency did not request new clinical studies, fixing CMC (chemistry, manufacturing, controls) issues can be time‑consuming and costly. AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.
AbbVie Company Profile
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Recommended Stories
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
